Omega Therapeutics, Inc. (OMGA)

Market Cap	46.34M
Revenue (ttm)	8.10M
Net Income (ttm)	-73.09M
Shares Out	55.37M
EPS (ttm)	-1.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,690
Open	0.800
Previous Close	0.812
Day's Range	0.793 - 0.880
52-Week Range	0.750 - 6.300
Beta	1.68
Analysts	Strong Buy
Price Target	9.20 (+999.3%)
Earnings Date	Nov 14, 2024

About OMGA

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 94
• Stock Exchange: NASDAQ
• Ticker Symbol: OMGA
• Website: https://omegatherapeutics.com

Financial Performance

In 2023, Omega Therapeutics's revenue was $3.09 million, an increase of 49.25% compared to the previous year's $2.07 million. Losses were -$97.43 million, -5.13% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for OMGA stock is "Strong Buy." The 12-month stock price forecast is $9.2, which is an increase of 999.30% from the latest price.

Price Target

$9.2

(999.30% upside)

Analyst Consensus: Strong Buy